NUT carcinoma, an under-recognized malignancy: a clinicopathologic and molecular series of 6 cases showing a subset of patients with better prognosis and a rare ZNF532::NUTM1 fusion

• Published in: Human pathology 2022-08, Vol.126, p.87-99
• Main Authors: Abreu, Rodrigo Fonseca, Oliveira, Thiago Bueno de, Hertzler, Hans, Toledo, Ronaldo Nunes, D'Almeida Costa, Felipe, Lopes Pinto, Clóvis Antonio, Nunes, Warley Abreu, Nascimento, Alessandra F., French, Christopher Alexander, Nascimento, Antonio Geraldo
• Format: Article
• Language: English
• Subjects: Antibodies; BRD3; BRD4; Cancer; Cytoplasm; Exocrine glands; Hospitals; Lymphatic system; Medical prognosis; Midline; Morphology; NUT carcinoma; NUTM1; Pathology; Patients; Sinuses; Tumors; ZNF532
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2022.05.015

NUT carcinoma (NC) is a rare malignancy with aggressive clinical behavior, defined by rearrangements involving the NUTM1 gene locus. This entity is often under-recognized and its diagnosis may be challenging. In this study, we describe a subset of patients that, despite the molecularly proven diagnosis of NC, show improved outcomes. In addition, we describe one case with the novel ZNF532::NUTM1 fusion. All cases of NC diagnosed from 2013 to 2022 in our department were retrieved. FISH using dual color bring-together probes and next-generation sequencing assay were performed to characterize the fusions involving NUTM1. Among 6 patients identified, 5 were men with a median age of 35.6 years. Four patients had primary tumors in the head and neck region (2 ethmoid sinus, 1 parotid gland, and 1 lacrimal gland); 1 in the mediastinum, and another presented with a femoral bone tumor. In all cases, the initial diagnoses were not NC. The cases showed different morphological patterns, including monomorphic, rhabdoid, and pleomorphic appearances. One case showed a pseudopapillary pattern. By immunohistochemistry, all tumors showed squamous differentiation and ≥50% of neoplastic cells with nuclear positivity for NUT antibody. One case expressed WT1 (C-terminus) and other showed chromogranin positivity. Genetic study revealed a BRD4::NUTM1 fusion in all head and neck cases, BRD3::NUTM1 in mediastinum case, and ZNF532::NUTM1 fusion in the femur bone case. They were treated with surgical resection plus chemotherapy and radiotherapy. The median overall survival was 23.11 months (1.6–83.3 months) and the median disease-free survival was 14.86 months (0–54.4 months). The patients with longer overall survival were one with a lacrimal gland primary (83.3 months) and other with a parotid lesion (31.9 months). Both patients were primarily treated with complete surgical resection. Anatomic location may be directly related to the overall survival in NC cases. Resectability of the lesion is also an important factor related to survival. Pathologists should include NC in the differential diagnosis of any poorly differentiated and undifferentiated monomorphic malignancy, regardless of its anatomic location. •NUT carcinoma is a rare malignancy with aggressive clinical behavior, defined by rearrangements involving the NUTM1 gene locus.•We highlight differents morphologic patterns, including monomorphic, rhabdoid, pleomorphic and pseudopapillary appearances, and one case with the novel ZN